Related Experiment Video
Updated: May 22, 2026
08:02
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
Published on: August 14, 2015
Lamotrigine use in pregnancy
James Layne Moore1, Puja Aggarwal
1The Ohio State University, Department of Neurology, 395 W 12th Ave, 7th Floor, Columbus, OH 43210, USA. j.layne.moore@osumc.edu
Expert Opinion on Pharmacotherapy
|May 19, 2012
Summary
Lamotrigine, an antiepileptic drug (AED), is a safe choice for women with epilepsy who are pregnant. Pregnancy registries show it has low risks for fetal malformations and cognitive development.
Area of Science:
- Neurology
- Pharmacology
- Teratology
Background:
- Antiepileptic drugs (AEDs) are used to treat epilepsy.
- AED use during pregnancy is linked to risks of fetal malformations and developmental issues.
- Choosing an appropriate AED for women of childbearing potential is critical.
Purpose of the Study:
- To evaluate the safety of lamotrigine during pregnancy.
- To compare lamotrigine's safety profile with other AEDs regarding fetal development.
- To inform clinical decisions for women with epilepsy planning pregnancy.
Main Methods:
- Review of international pregnancy registries.
- Analysis of data on fetal malformations following AED exposure during organogenesis.
- Assessment of postpartum cognitive development in children exposed to AEDs in utero.
Main Results:
- Lamotrigine is associated with a lower risk of fetal malformations compared to other AEDs.
- Postpartum cognitive development in infants exposed to lamotrigine is not significantly affected.
- Lamotrigine demonstrates a favorable safety profile for both fetal and infant development.
Conclusions:
- Lamotrigine is considered one of the safest AEDs for pregnant women with epilepsy.
- Its established safety profile makes it a preferred choice for women planning pregnancy.
- Further research may solidify lamotrigine's role as a first-line AED in this population.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...